The combination of C26A6 with either Erastin (system Xc- inhibitor)33 and ML-162 (GPX4 inhibitor)51 showed a synergistic effect in different ovarian cancer cell lines (Supplementary Fig. 4,5). This evidence concerns the gene GPX4 and ovarian cancer.